Axsome Therapeutics (AXSM) Competitors $112.29 +2.37 (+2.16%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM vs. SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, and ROIVShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Axsome Therapeutics vs. Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Summit Therapeutics (NASDAQ:SMMT) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Is SMMT or AXSM more profitable? Summit Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Summit Therapeutics' return on equity of -85.42% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Axsome Therapeutics -74.47%-223.51%-39.88% Does the MarketBeat Community believe in SMMT or AXSM? Axsome Therapeutics received 169 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 70.59% of users gave Axsome Therapeutics an outperform vote while only 58.57% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% Axsome TherapeuticsOutperform Votes48070.59% Underperform Votes20029.41% Does the media prefer SMMT or AXSM? In the previous week, Summit Therapeutics had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 26 mentions for Summit Therapeutics and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.20 beat Summit Therapeutics' score of 0.70 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SMMT or AXSM? Summit Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 56.32%. Axsome Therapeutics has a consensus target price of $169.87, suggesting a potential upside of 51.03%. Given Summit Therapeutics' higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, SMMT or AXSM? Axsome Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K25,281.35-$614.93M-$0.31-77.39Axsome Therapeutics$385.69M14.22-$287.22M-$5.99-18.78 Which has more volatility & risk, SMMT or AXSM? Summit Therapeutics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Do insiders and institutionals hold more shares of SMMT or AXSM? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAxsome Therapeutics beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.48B$6.85B$5.54B$7.74BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-18.787.4322.4118.43Price / Sales14.22241.53393.33103.32Price / CashN/A65.8538.1834.62Price / Book95.316.496.724.23Net Income-$287.22M$143.21M$3.22B$248.23M7 Day Performance7.88%3.62%2.83%2.95%1 Month Performance-5.11%0.07%-0.36%2.11%1 Year Performance52.48%2.67%17.84%5.31% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.8344 of 5 stars$112.29+2.2%$169.87+51.3%+52.2%$5.48B$385.69M-18.75380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsSMMTSummit Therapeutics2.6645 of 5 stars$25.18+2.3%$35.40+40.6%+513.7%$18.57B$700,000.00-89.93110Analyst ForecastGap DownTEVATeva Pharmaceutical Industries3.2638 of 5 stars$13.25-2.9%$23.43+76.8%+10.5%$15.02B$16.54B-9.1436,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8812 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4452 of 5 stars$20.11+0.3%$39.17+94.8%-23.6%$13.31B$21.53B11.561,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8436 of 5 stars$13.66-0.1%$17.00+24.5%-5.3%$11.40B$311.31B21.7524,800Upcoming EarningsASNDAscendis Pharma A/S2.3344 of 5 stars$159.83-3.2%$204.67+28.1%+23.1%$9.74B$363.64M-22.51640Positive NewsMRNAModerna4.3377 of 5 stars$25.17+1.8%$58.70+133.2%-74.1%$9.73B$3.20B-2.713,900VTRSViatris1.8348 of 5 stars$7.56flat$10.50+38.9%-27.2%$9.02B$14.74B-10.2237,000Upcoming EarningsQGENQiagen3.6786 of 5 stars$40.49-0.5%$47.83+18.1%+4.0%$9.00B$1.98B112.746,030Upcoming EarningsAnalyst RevisionNews CoverageROIVRoivant Sciences2.1639 of 5 stars$10.06-0.9%$17.50+74.0%+6.6%$7.18B$122.59M-67.06860 Related Companies and Tools Related Companies SMMT Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXSM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
